Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence

Purpose of review Prostate-specific membrane antigen targeted PET imaging (PSMA PET) of biochemically recurrent prostate cancer (BCR) is implemented in routine management in many countries and recommended in European Association of Urology (EAU) and American Society of Clinical Oncology (ASCO) guidelines. Purpose of this review is to summarize recently published evidence of accuracy, management impact, and clinical benefit of PSMA PET in this setting and to state our opinion on the role of PSMA PET in future trials and clinical routine to improve patient outcomes. Recent findings The past two years saw an increase of evidence supporting superior detection rates and accuracy of PSMA PET versus standard imaging and other PET radiotracers in the localization of BCR. Systematic reviews, prospective trials and large-scale retrospective studies establish PSMA PET as a new benchmark imaging in this setting and demonstrate considerable impact on therapeutic and diagnostic management. Multiple studies have highlighted pitfalls of PSMA PET imaging warranting attention while interpreting these scans. Summary PSMA PET is the new imaging method of choice in BCR. Recent evidence shows unprecedented accuracy and high detection rates along with translation into management changes in a majority of patients. However, improvement of oncologic outcome has not been assessed yet. Implementation of PSMA PET into clinical trials and management of BCR will be crucial to demonstrate outcome im...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PET IMAGING IN UROLOGY: Edited by Stefano Fanti and Declan G. Murphy Source Type: research

Related Links:

CONCLUSION: Our results show that BxPNI could be considered as a risk classification factor to identify the best candidates among younger PCa patients for further treatment and may also be used for developing active surveillance (AS) selection criteria for younger PCa patients. PMID: 32930036 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Cancers, Vol. 12, Pages 2654: Analysis of Bone Scans in Various Tumor Entities Using a Deep-Learning-Based Artificial Neural Network Algorithm—Evaluation of Diagnostic Performance Cancers doi: 10.3390/cancers12092654 Authors: Jan Wuestemann Sebastian Hupfeld Dennis Kupitz Philipp Genseke Simone Schenke Maciej Pech Michael C. Kreissl Oliver S. Grosser The bone scan index (BSI), initially introduced for metastatic prostate cancer, quantifies the osseous tumor load from planar bone scans. Following the basic idea of radiomics, this method incorporates specific deep-learning techniques (artificial n...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Piccardo A, Ugolini M, Righi S, Bottoni G, Cistaro A, Paparo F, Giovanella L, Evangelista L Abstract Copper is an essential element that plays an important role in both cancer development and growth. Indeed, high levels of copper have been found in prostate cancer (PCa), and this finding have paved the way for the use of this element as a target for positron emission tomography (PET) imaging. Copper64 (64Cu) can be used alone, as 64CuCl2, and also as a precursor for the in vitro radio-labelling of specific carriers for PET imaging in PCa, (e.g. associated to prostate-specific membrane antigen: PSMA). The u...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
In this study of Chinese men with biochemical recurrence, added value for the detection of lesions compatible with sites of PCa was found with68Ga-PSMA-11 PET/CT over conventional imaging. The observed patterns of disease spread may have implications for understanding the biology of early prostate cancer metastasis.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to evaluate the optimal method for planning computed tomography (CT) for prostate cancer radiotherapy to avoid a dose difference of ≥3% between the actual and planned treatments using multiple acquisition planning CT (MPCT). We calculated the 3-dimensional (3D) displacement error between the pelvic bone and matching fiducial marker on MPCT and cone-beam CT scans of 25 patients who underwent prostate volumetric-modulated arc th erapy for prostate cancer. The correlation of the 3D displacement error and the dose difference between planned and actual treatments was calculated using least squares second-order polynomial model.
Source: Medical Dosimetry - Category: Radiology Authors: Source Type: research
Multiple prostate-cancer directed positron emission tomography (PET) radiotracers have emerged and (18)F-fluciclovine (Axumin) is the most recent agent that has been approved by the US Food and Drug Administration for detection of recurrent prostate cancer (PCa).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Prostate cancer (Pca) is the most common cancer and the second leading cause of death among men. Although conventional bone scans and abdominal CT are preferred in most of the guidelines and clinical trials, PET/CT has already started to become the inevitable part of Pca management because of its higher sensitivity and specificity. Radiotracers used for PET imaging show different molecular aspects of the disease process. Although 68Ga–prostate-specific membrane antigen offers the highest sensitivity and specificity, other PET radiotracers such as 18F-FDG and 68Ga-DOTATATE still have a role in patients with prostate-s...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
A 56-year-old man with metastatic castration-resistant prostate cancer was referred for radioligand therapy with 177Lu–prostate-specific membrane antigen. In the third cycle, a posttherapy whole-body scan showed unexpected skeletal and joint uptake apart from his known metastatic lesions. This observation raised suspicion for possible impurity (mainly free lutetium) in the applied radiopharmaceutical product. After contacting the radiopharmaceutical company, we were informed that the radiochemical purity of the used batch of 177Lu–prostate-specific membrane antigen had been 95%. This is the first report of exce...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
CONCLUSIONS: pTULSA appears safe and feasible for palliative ablation of locally advanced prostate cancer. The therapy seems to accomplish long-term hematuria control, can relieve bladder outlet obstruction in selected patients, and seems to reduce the burden of hospitalization due to local complications. Trial Registration Number: NCT03350529. PMID: 32897169 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Lung cancer is the second most prevalent cancer in the US, and the deadliest cancer killer. In 2020, an estimated 135,720 people will die from the disease — more than breast, colon, and prostate cancers combined. I’ll never forget meeting new, advanced-stage lung cancer patients who ask if their diagnosis could have somehow been made earlier, when treatment would have been more likely to succeed. In 2009, when I began practicing thoracic oncology, there were no approved screening tests for lung cancer. A brief history of lung cancer screening Hope for early detection and death prevention came in 2011 with the p...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Lung disease Screening Source Type: blogs
More News: Cancer | Cancer & Oncology | Clinical Trials | PET Scan | Prostate Cancer | Study | Urology & Nephrology